Logo
x

Search

Subscribe Now

high-risk

Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant

Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant

  • October 27, 2021
BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

  • August 23, 2021
BeiGene and EUSA Receive the NMPA's Approval of Qarziba (dinutuximab beta) for High-Risk Neuroblastoma

BeiGene and EUSA Receive the NMPA's Approval of Qarziba (dinutuximab beta) for High-Risk Neuroblastoma

  • August 18, 2021
BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma

BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Car...

  • September 25, 2020
Merck & Co's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Merck & Co's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with BCG-Unresponsive High-Risk Non-Muscle I...

  • January 9, 2020
Astellas' ASP1128 Receives the US FDA's Fast Track Designation for Patients at High Risk of Acute Kidney Injury

Astellas' ASP1128 Receives the US FDA's Fast Track Designation for Patients at High Risk of Acute Kidney Injury

  • October 29, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.